UBS lowered the firm’s price target on Salesforce (CRM) to $320 from $340 and keeps a Neutral rating on the shares. A guidance reaffirmation for growth seems “most likely,” the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRM:
- Salesforce (NYSE:CRM) Expands Its Reach in Healthcare and Government Sectors
- Veeva has ‘meaningful’ Life Science head start over Salesforce, says Oppenheimer
- KeyBanc still expects Veeva to retain majority of CRM customers
- Takeda selects Salesforce Life Sciences Cloud for Customer Engagement
- Salesforce, GSA announce collaboration to lower price of Slack
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue